Plan ahead

Plan ahead of these events, and schedule time with us!

We can help you:


Understand the landscape in seconds for the targeted therapy of your choice.

Book a demo

To book a live demo to show you how this works specifically to your questions.

Events Beacon will be attending

6th Annual Allogeneic Cell Therapies Summit 2024

June 10 – 12, 2024 | Boston, NMA

2024 is shaping up to be a vitally important year for the future of allogeneic cell therapies. With exciting clinical data readouts expected in the coming months and the cell therapy community recognizing autoimmune indications as the promising new cornerstone of research – the tide is shifting for off-the-shelf therapies.

Placing a spotlight on what has been deemed the ‘future of cell therapy’, the 6th Annual Allogeneic Cell Therapies Summit returns to Boston this June as the leading industry-focused meeting dedicated to accelerating the safety, durability, and clinical translation of off-the-shelf therapies to deliver affordable and accessible treatments for patients in critical need.

Don’t miss this golden opportunity to connect with other cell therapy leaders to accelerate your allogeneic pipelines in 2024 and beyond! Rachel East, our Research Analyst, joins allogeneic trailblazers to present a full landscape overview of the allogeneic cell therapy space on Day 1 so make sure you don’t miss out! Access the full presentation details here.

Find out more

4th Next Generation Gene Therapy Vectors Summit 2024

June 12 – 14, 2024 | Boston, MA

As the first wave of gene therapy programs continues to progress into and through the clinic, attention turns to finding and optimizing the next generation of improved vector candidates. With delivery challenges cited by many as the limiting factor for progress in the field, significant investment continues to pour into improving the safety, efficacy, and predictability of delivery platforms.

In this setting, the 4th Next Generation Gene Therapy Vectors Summit is returning as the only industry-focused event covering the latest advances and innovations in vector development for gene therapies.

Our Senior Research Analyst, Costanza Gorini, will be setting the scene on conference Day 1 with an overview of the current landscape of next-generation gene therapy, so do not miss this ultimate roadmap of the space! Access the full breakdown of the presentation here. Join the world’s experts in Boston to keep your finger on the pulse and support your vector development efforts for 2024 and beyond.

Find out more

5th STING & TLR-Targeting Therapies Summit 2024

June 18 – 20, 2024 | San Diego, CA

The STING & TLR Targeted Therapies Summit returns as the only industry-led event converging those with crucial insights to fuel the long-awaited success of innate immunity-targeted therapies.

With the field venturing into new approaches to strike that balance between safety and efficacy, from immune agonist conjugates to combination approaches and novel dosing methods, stay ahead of this evolving field with the latest insights to steer you toward success in the clinic.

Presenting ‘An Overview of the Current Development, Clinical Trials & Key Players in the STING & TLR Landscape‘, our Research Analyst, Zer En Peng, joins the expert community and trailblazers to provide actionable insights to unlock the potential of harnessing the innate immune system to meet unmet needs. Access the full presentation details now.

Find out more

3rd World ADC Asia 2024

June 25 – 27, 2024 |  Incheon, South Korea

The year 2024 has been considered the ‘coming of age’ era for antibody-drug conjugates, in great part due to the remarkable resurgence in drug development across the Asia-Pacific region. This part of the world is taking the ADC industry by storm with high-profile deals, multiple approvals, multiple ADCs moving into clinical trials, and novel targets being explored just to name some advancements.

Back by popular demand after a short break, the 3rd World ADC Asia is bringing together pioneers and key opinion leaders across mega-pharma and biotechnology focusing on China, Japan, Taiwan, South Korea and Singapore. They’ll be sharing their most pressing challenges, novel payloads, conjugationand linker innovations to inform ADC development and improve targeting accuracy.

Alongside a phenomenal speaker faculty, our ADC Technical Lead and Researcher, Jia He, will be exploring the flourishing landscape. Taking time to review the clinical and preclinical space, and analyzing trends in this recent flurry of ADC deals, this is one not to be missed! Uncover the full presentation details today.

Find out more

3rd Cell Therapy Analytical Development Summit Europe

September 3 – 5, 2024 | London, UK

With regulatory bottlenecks significantly delaying the process of characterisation to method validation and release, the European cell therapy community is actively seeking a central hub to collaborate, connect and share insights to drive the future development of cell therapies forward.

Returning to London this September, the 3rd Cell Therapy Analytical Development Summit Europe is the definitive summit dedicated to defining and refining analytics to ensure the swift progression of highly efficacious products through IND/IMPD and clinical trials.

Uniting pioneering analytical development and quality control experts from Achilles Therapeutics, Avobis Bio, Bristol Myers Squibb, Johnson & Johnson, GSK, and MHRA, this summit is your one-stop shop to spearhead the future of analytical innovation. 

Discover the full 3-day agenda details here.

Find out more

15th World Bispecific Summit 2024

September 3 – 5, 2024 | Boston, MA

The 15th World Bispecific Summit has established itself as the key biopharma-directed event to gain clear insights into the latest advancements and future directions amongst the mass of bispecific antibodies currently being developed and how to address associated development challenges encountered within this therapeutic modality.

If your research teams are looking to keep ahead of the next wave of bispecific antibodies currently in development, join this event to learn how experts are leveraging pioneering new formats like bispecific ADCs and exciting targets like peptide-HLA complexes whilst managing developability and risk.

Presenting ‘A Review of the Bispecific Landscape: The Past, The Present & The Future of Biologics’ our Research Analyst, Flavio Lima Bianchi will be reviewing drug and trial landscapes, discussing the emerging trends in the space, and looking towards the future of the bispecific industry.

Discover the 3-day agenda and Flavio’s talk in more detail here.

Find out more